Co-Diagnostics has signed an agreement with DNA Logix, a molecular diagnostic assays developer, to buy certain technologies for genetic analysis in the clinical, industrial, and bio-threat segments.
The technology to be gained is embodied in three patent applications and certain trade secrets that enable DNA testing with sensitivity and specificity.
The technology is expected to help Co-Diagnostics in the development of assay and reduction of costs for the end user.
Co-Diagnostics president Dwight Egan said that DNA Logix’s experience in providing the technology for developing molecular diagnostics in the oncology and infectious disease arena is being recognized by diagnostic manufacturers and pharmaceutical partners.
"With this technology, we believe our highly efficient assay development capability, combined with superior results and efficient costs, will result in our unique approach to DNA testing being sought after by developers of powerful diagnostics in a wide range of markets," Egan added.